OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Chagpar on Financial Toxicity and Disparities in Breast Cancer

March 4th 2023

Anees Chagpar, MD, MBA, MPH, FACS, FRCS(C), discusses the unmet needs regarding financial toxicities for patients with breast cancer.

Dr. Petrylak on Results From the KEYNOTE-921 Trial of Pembrolizumab Plus Docetaxel in mCRPC

March 3rd 2023

Daniel P. Petrylak, MD, discusses efficacy and safety data from the phase 3 KEYNOTE-921 trial of pembrolizumab and docetaxel in metastatic castrate-resistant prostate cancer.

Dr. Chmura on the Management of Oligometastatic Breast Cancer

March 3rd 2023

Steven J. Chmura, MD, PhD, discusses the current management strategies for oligometastatic breast cancer.

Dr. Kalinsky on the Evolving Treatment Landscape and Sequencing ADCs in TNBC

March 3rd 2023

Kevin Kalinsky, MD, MS, discusses the evolving treatment landscape for patients with triple-negative breast cancer and how to best sequence antibody-drug conjugates within this population.

Dr. Hunt on Axillary Reverse Mapping in Breast Cancer

March 3rd 2023

Kelly K. Hunt, MD, FACS, FSSO, discusses technical considerations for axillary reverse mapping in breast cancer for the reduction or prevention of lymphedema.

Dr. Bander on Preliminary Data on 225Ac-J591 Plus Pembrolizumab in mCRPC

March 3rd 2023

Neil H. Bander, MD, discusses preliminary results from a phase 1/2 study of pembrolizumab in combination with an androgen-receptor signaling inhibitor and alpha-PSMA-targeted radionuclide therapy in mCRPC.

Dr. Esserman on the I-SPY2 Trial in Breast Cancer

March 3rd 2023

Laura J. Esserman, MD, MBA, discusses the rationale and design for the phase 2 I-SPY2 trial.

Dr. Hassan on the Importance of Accurate Molecular Profiling in Lung Cancer

March 3rd 2023

Khaled Hassan, MD, discusses the importance of performing precise molecular profiling in patients with lung cancer and the need to identify individually tailored treatment approaches.

Dr. Saeed on Biomarkers That Influence Treatment Decisions in ESCC

March 2nd 2023

Anwaar Saeed, MD, discusses biomarkers that signal the potential efficacy of frontline immunotherapy regimens in patients with advanced esophageal squamous cell carcinoma.

Dr. Vidal on the Role of Social Determinants of Health in Breast Cancer Care

March 2nd 2023

Gregory Vidal, MD, PhD, discusses racial disparities in the treatment of patients with breast cancer.

Dr. Mato on the Potential Use of Noncovalent BTK Inhibitors in CLL

March 2nd 2023

Anthony Mato, MD, MSCE, discusses recent data on the emerging class of noncovalent BTK inhibitors in chronic lymphocytic leukemia and their potential advantage over currently approved covalent BTK inhibitors.

Dr. Pavlick on Addressing Unmet Needs in Melanoma Through Ongoing Investigation

March 2nd 2023

Anna C. Pavlick, DO, discusses how ongoing research efforts at Weill Cornell Medicine are attempting to ameliorate unmet needs in melanoma.

Dr. Koo on Novel Technological and Therapeutic Advancements in Prostate Cancer

March 1st 2023

Phillip J. Koo, MD, discusses ongoing areas of technological and therapeutic advancements within the prostate cancer landscape.

Dr. Chatzkel on the Rationale for the IMMCO-1 trial in mCRPC and Other Immunologically Cold Tumors

March 1st 2023

Jonathan Chatzkel, MD, discusses the rationale for the phase Ib/II IMMCO-1 trial investigating the combination of atezolizumab plus tivozanib in metastatic castration-resistant prostate cancer and other immunologically cold tumors.

Dr. Braun on the Role of SLAMF7+ CD8+ T-cells in Nivolumab-Resistant RCC

March 1st 2023

David A. Braun, MD, PhD, discusses the enrichment of SLAMF7-positive, CD8-positive T-cells and their role on nivolumab resistance in clear cell and non–clear cell renal cell carcinoma.

Dr. Shore on the Long-term Safety of Darolutamide in nmCRPC

March 1st 2023

Neal Shore, MD, FACS, US discusses the continued evaluation of darolutamide in patients with non-metastatic castration-resistant prostate cancer.

Dr. O’Shaughnessy on Adjuvant Abemaciclib in High-Risk Early Breast Cancer

March 1st 2023

Joyce O’Shaughnessy, MD, discusses the findings from the phase 3 monarchE trial of adjuvant endocrine therapy with or without abemaciclib in patients with hormone receptor–positive, HER2-negative, node-positive, high-risk early breast cancer.

Dr. Chen on the Efficacy of Vedolizumab Prophylaxis for aGVHD in the GRAPHITE Trial

March 1st 2023

Yi-Bin Chen, MD, discusses key data on the use of vedolizumab in lower gastrointestinal acute Graft-Versus-Host Disease according to the phase 3 GRAPHITE study.

Dr. Muffly on the Evaluation of Briquilimab Conditioning Prior to HSCT in AML

February 28th 2023

Lori Muffly, MD, discusses the clinical outcomes with the use of a novel conditioning regimen featuring the anti-CD117 monoclonal antibody briquilimab plus low-dose irradiation and fludarabine prior to allogeneic hemopoietic stem cell transplant in older patients with acute myeloid leukemia.

Dr. Fingrut on the Association Between Ancestry, Socioeconomic Status, and HLA-Disparate Grafts

February 28th 2023

Warren Fingrut, MD, discusses the association between non-European ancestry and low socioeconomic status with the receipt of HLA-disparate grafts.